Best Life Sciences Platforms and Tools Companies in Zurich, Switzerland

Developer of nanotechnology reagents and protocols for RNA and protein detection. The platform incorporates a nanotechnology-based signal amplification system. This system permits simultaneous multiplex target detection and is multimodal for applications like immunofluorescence and imaging mass cytometry. Designed for ease of use, it requires no specialized laboratory equipment. Scientific researchers in cell biology and genomics can perform accurate, high-throughput biomolecule quantification. This quantification complements other data analysis methods like RNA sequencing.

Funding rounds

• Nov 2025Seed$7.8M

Founders & team

Scott FraserCo-FounderKaspar BinzChairman of the board of directors & co-founderSimon RestrepoCo-Founder

Investors

ZEISS, Zurcher Kantonalbank

Haelixa provides intelligent DNA-based tracing solutions allowing fluid/item tracking and parameter monitoring (temperature, light, pH, oxidants) to support the energy industry (underground exploration and monitoring), and ensure product authentication and quality control as well as liability management. The tracers are composed of DNA sequences encapsulated within invisible particles that can be mixed with any fluid and item, providing it with a unique fingerprint, which is easily identified and quantified at parts per trillion level (1 milligram per ton) with bio-analytics used in medicine and forensics. The use of DNA permits to generate as many distinct fingerprints as are needed as unlimited DNA sequences are available. The encapsulation improves DNA stability, providing resilience in harsh conditions. Both DNA and particles can be engineered to obtain tracers capable of determining temperature, pH, oxidant concentration, light intensity. The main applications of the technology currently are - Reservoir Monitoring (characterize and monitor oil or geothermal reservoirs by tracking the movement of fluids in the subsurface) and Product Authentication (transparent identification a

Funding rounds

• Feb 2026Seed$2.4M
• Sep 2019Seed—
• Sep 2017Grant (prize money)$730.2K
• 2017Seed$127.5K

Founders & team

Patrick StrumpfCEO

Investors

Zurcher Kantonalbank, Verve Ventures, Venture Kick, Europa, 212 Vc

Tech stack

Alpine.JsCdnjsCloudflareCloudflare Bot ManagementCloudflare StreamComplianz

Provides functional cancer profiling using biomarker analysis. Its assay platform uses biomarkers and genetic profiles and provides information about the best possible proximation of the patient’s response from multiple therapeutic options. It helps a physician for choosing effective therapy for cancer treatment. Its offering is an analysis of biomarkers and genetic profiles for precision medicine.

Funding rounds

• Dec 2024Series A—
• Oct 2022Seed$1.3M
• Apr 2021Seed$2.4M

Founders & team

Jens KelmCo-Founder

Investors

HTGF, FiveT, Kinled Holding, LongeVC, Koodos, HEMEX

Tech stack

Apache Http ServerContact Form 7CookiebotCore-JsElementorFlickity

Microcaps develop microfluidic-based technology. Their technology enables to development of monodisperse capsules and emulsions of various sizes. The microparticles and microcapsules are used to protect active materials (in drug development). The monodisperse capsules are developed at industrial scale.

Funding rounds

• Jun 2024Series A$10.4M
• Jan 2021Seed$5.6M
• Feb 2019Seed$130K

Founders & team

Alessandro OfnerCo-FounderMichael HaganderCo-Founder

Investors

Venture Kick, Helvetica Capital, Zurcher Kantonalbank, Lichtsteiner Foundation, Ethereum, AIT Startups

Tech stack

ElementorHttp/3JqueryJquery MigrateLitespeed CacheMailjet

Developer of cell-based assays for drug screening. The organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell invasion assays, cell-to-cell interaction, cell-to-extracellular matrix interaction services. The company is focused on providing assays for metabolic diseases, oncology, and liver diseases.

Funding rounds

• Mar 2023Series D—
• Jun 2020Grant (prize money)$56.2K
• Jan 2020Grant (prize money)$56.1K
• Jun 2018Series C$10M

Founders & team

Jan LichtenbergChief Executive Officer and Board Member

Investors

Venture Kick, Europa, Redalpine, Zurcher Kantonalbank, ZEISS, Venturelab

Tech stack

AstraBackbone.JsCloudflareCloudflare Bot ManagementCookieyesCore-Js

Developer of novel antibody-drug conjugate linker technology. It offers a proprietary peptide linker technology enabling efficient, site-specific payload attachment to antibodies. This results in homogenous, stable, and highly soluble antibody-drug conjugates (ADCs) with improved efficacy and reduced side effects. The technology simplifies manufacturing by using off-the-shelf antibodies, reducing development time and costs. The improved linker solubility minimizes aggregation, ensuring efficient binding to cancer cells. This approach offers a significant advancement in ADC development, leading to safer and more potent cancer therapies.

Funding rounds

• Apr 2023Series A—
• Oct 2022Series A$24.3M
• Oct 2020Seed$14M
• Aug 2019Seed$2.6M

Founders & team

Dragan GrabulovskiCo-Founder & CEOPhilipp SpycherCo-Founder & CSO

Investors

Redalpine, Schroders Capital, VI Partners, 4Bio Capital, Pureos Bioventures, Wille Finance

Tech stack

Apache Http ServerGoogle AnalyticsGoogle Font ApiHostpointJqueryMicrosoft 365

Developer of drugs for multiple diseases. The company is developing therapeutics for multiple indications such as antibody therapy for obesity, nanovesicles therapy for arthritis, antibody therapy for acute lymphocytic leukemia among others. The platform also offers services such as 3D bioprinting and AI-based software for cancer diagnosis among others.

Funding rounds

• Dec 2020Series C$6.7M
• Nov 2019Series C$56.1M

Founders & team

Oliver BaumannCEO

Tech stack

CloudflareCore-JsGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGsap

Manufacturer of key components for NMR spectrometers intended to provide efficient methods in product development. The company provides innovative solutions with performance for demanding applications in NMR spectroscopy, demonstrating enhanced performance compared to current products on the market, thereby enabling its clients to avail the solutions at affordable prices.

Developer of instruments, reagents, and kits for rapid pathogen detection. The product portfolio of the company includes a sample preparation instrument system, reagents, and kits. Also, provide detection services which uses an immunomagnetic separation-based method to separate the target cells from the sample. The isolated cells are analyzed using flow cytometry.

Funding rounds

• Mar 2021Grant (prize money)$58.7K
• Mar 2021Series B$6.5M
• Sep 2018Grant (prize money)$2.6M
• Feb 2018Grant (prize money)$61.5K

Founders & team

Hans-Anton KeserueFounder & CEODaniel SchaffhauserCo-Founder & CTO

Investors

Europa, EIC Fund, Startup Caddie, Venturelab, MassChallenge

Provider of web hosting, domain registration, and related support services. The company offers technical assistance via email and telephone. Support for billing inquiries is also available during business hours. Additional phone numbers are provided for sales, support, domains, invoices, and payments.

Manufacturer of motor-based process equipment. It supplies systems for microelectronics and bioprocessing applications. Products include pumps, flow controllers, sensors, mixers, and fans for various processes such as perfusion, filtration, and chemical delivery. It specializes in supplying blood pumps to the medical community and ultra-pure fluid handling devices for microelectronics, life science, and industrial applications.

Funding rounds

• Aug 2009Grant (prize money)$1.4M
• Mar 2009Grant (prize money)$1.4M
• Mar 2008Grant (prize money)$1.4M
• Sep 2007Grant (prize money)$1.4M

Founders & team

Reto SchobMDNatale BarlettaMDKurt DassePresident and CEO

Investors

HHS

Tech stack

CookieyesCore-JsHostpointJqueryJquery MigrateMatomo Analytics

Biognosys has developed two platforms in proteomics namely discovery proteomics and targeted proteomics. Discovery proteomics uses Hyper Reaction Monitoring (HRM), an in-house technology, to identify differentially expressed proteins. The technology involves statistical data analysis and quantification of the identified peptides. For targeted proteomics, they have developed Multiple and Parallel Reaction Monitoring (MRM and PRM) system, like HRM this involves the collection of assays for the desired protein and is used generally for pre-determined set of proteins of interest. The company offers following products based on these two technologies workflow kits(retention time normalization kit, HRM calibration kit, and sample preparation kit), Multiplexed assay panels(Plasma dive and Plasma deep dive), and software tools(Spetronaut and spectradive). Additionally, they offer services using their designed product.